Allogeneic Immunotherapy for Malignant Diseases (Basic and Clinical Oncology)

This important reference offers a comprehensive review of the graft-versus-leukemia (GVL) or -tumor (GVT) effect following allogeneic stem cell transplantation and lymphocyte transfusion, covering a wide range of topics from alloimmune responses to clinical applications of GVL, and providing the basics to understand the mechanisms of the GVL effect while demonstrating methods that use the GVL effect to cure a greater number of cancer patients. Presents preliminary data supporting the idea that allogeneic cell therapy can be used not only for the treatment of leukemia but also for metastatic solid tumors! Written by over 40 world renowned experts in the field and containing more than 1450 references for in-depth exploration of the subject, Allogeneic Immunotherapy for Malignant Diseases ·investigates the capacity of the donor-and the host-to destroy residual leukemia cells by allogeneic immune reaction ·determines how to direct immune reactions against hematopoietic malignancies safely ·reveals which other malignant conditions may be responsive to allogeneic-mediated graft-versus-tumor reactions ·covers the mechanisms that contribute to the development of responses to minor histocompatibility complex (mHC) molecules ·focuses on the biology of effector cells and their role in mediating GVL reactions in chronic myeloid leukemia (CML) ·summarizes the putative impact of human mHag on the GVL effect in bone marrow transplantation (BMT) ·addresses the potential and limitations of oncogene-based immunotherapy ·examines ways to isolate and control the GVL component of allograft immunity ·discusses efforts to develop specific anti-leukemic T-cell immunotherapy ·and more! Attributing the curative effect of allogeneic stem cell transplantation to the GVL or GVT effect, Allogeneic Immunotherapy for Malignant Diseases is an indispensable reference for hematologists, clinical oncologists, immunologists and researchers in the fields of tumor immunology and cancer immunotherapy, internists, residents, and medical school students in these disciplines.